



4-10
HP
4-30-02
NB

PATENT
Customer Number: 22,852
Attorney Docket No. 5394.0011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Stewart COLE et al.) Group Art Unit: 1634
Application No.: 09/673,476) Examiner: J. Souaya
International Appln. PCT/IB99/00740)
Filed: October 16, 2000)
International Filing)
Date: April 16, 1999)

RECEIVED
APR 08 2002
TECH CENTER 1600/2900

For: A METHOD FOR ISOLATING A POLYNUCLEOTIDE OF INTEREST FROM
THE GENOME OF A MYCOBACTERIUM USING A BAC-BASED DNA
LIBRARY, APPLICATION TO THE DETECTION OF MYCOBACTERIA

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES

In response to the Communication dated March 7, 2002, requesting compliance
with the Sequence Rules, 37 C.F.R. §§ 1.821-1.825, applicants submit the following
amendments and remarks.

IN THE ABSTRACT:

Please insert the attached Abstract following the claims.

IN THE DRAWINGS:

Please amend the Figures as indicated on the attached Request for Approval of
Drawing Changes submitted concurrently herewith. Specifically, applicants have
requested permission to amend Figures 6 and 7 to include appropriate SEQ ID Nos.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

IN THE SPECIFICATION:

Please replace the specification, as filed, with the substitute specification filed concurrently.

In the substitute specification, after page 131, and before the claims, beginning on a new page, please insert the attached sequence listing.

REMARKS

Claims 1-50 are pending in this application.

Abstract

Applicants submit with this response an abstract on a separate sheet of paper, as required by 37 C.F.R. § 1.72(b).

Substitute Specification

Applicants submit with this response a substitute specification pursuant to 37 C.F.R. § 1.125(b) as well as a marked up copy of the specification showing where amendments were made. Pursuant to 37 C.F.R. § 1.125(b)(1), the substitute specification contains no new matter and was amended to add the appropriate SEQ ID Nos. and to correct typographical errors.

Sequence Listing

In a Communication dated March 7, 2002, the Office noted that this application failed to comply with the requirements of the sequence rules. Specifically, the Office noted that applicants were required to submit a copy of the Sequence Listing in

computer readable form, a paper copy of the sequence listing, as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same.

Applicants submit with this response a copy of the Sequence Listing in computer readable form, a paper copy of the sequence listing, an amendment directing its entry into the substitute specification, and the appropriate statement.

If there is any fee due in connection with the filing of this paper, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 4, 2002

By: 

Timothy B. Donaldson
Reg. No. 43,592

Tel: (202) 408-4000
Fax: (202) 408-4400
Email: timothy.donaldson@finnegan.com

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com